BYSI BeyondSpring Inc.
USHealthcareAs of 2026-07-10 13:22
Why BYSI matters now
BeyondSpring Inc. (BYSI) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.46 with -2.03% on the session and $60.0M in market capitalization; recent performance reads 1-month +24.81% and YTD -1.23%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.2M, and EPS of $-0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -28.8%.
The latest indexable market news headline is "BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Huang Lan filing G-Gift. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-1.92
P/S
0.00
EV/EBITDA
-7.79
DCF Value
$0.18
FCF Yield
-28.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
23.8%
ROA
-41.5%
ROIC
-136.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.2M | $-0.05 |
| Q4 2025 | $0.00 | $-2.1M | $-0.05 |
| FY 2025 | $0.00 | $-8.0M | $-0.20 |
| Q3 2025 | $0.00 | $-1.5M | $-0.04 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.42
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.